Share 0
Share 0
Post 0

Multi-registry study highlights ocrelizumab’s superior relapse control in multiple sclerosis

Wednesday, September 24th, 2025

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.

WE WANT YOU!

are you a developer?

  • Proven International Track Record
  • Vertically Integrated Federal Funds
  • Vertically Integrated Tax Credits
  • Vertically Integrated Investors
  • Vertically Integrated Lenders
  • Vertically Integrated Contractors
 List your project

Report

Contains abusive or threatening content.
There has been a breach of confidentiality.
There has been a breach of contract.
There has been a breach of fiduciary within a partnership.
Contains mature, sensitive, or otherwise inappropriate content.
Contains misleading or false information with perceived intent.
Harassment or otherwise unwanted, unprofessional, or excessive communication or attempted communication.
Contains spam, potential malware, or otherwise not generally professional content.

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .